References

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

10.1182/blood-2016-01-643569 · 2016 · External reference

Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium

10.1200/jco.19.00743 · 2019 · External reference

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

10.1200/jco.2011.41.0985 · 2012 · External reference

CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature–expressing DLBCL

10.1182/blood.2024025725 · 2025 · External reference

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP

10.3324/haematol.2009.007203 · 2010 · External reference

MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis

10.1111/his.12884 · 2016 · External reference

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

10.1182/blood-2014-05-578963 · 2014 · External reference

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

10.1038/s41375-019-0691-6 · 2020 · External reference

A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications

10.1016/j.ccell.2020.03.015 · 2020 · External reference

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

10.1038/s41591-018-0016-8 · 2018 · External reference

Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL

10.1182/bloodadvances.2023010673 · 2023 · External reference

Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma

10.1200/jco.18.01583 · 2019 · External reference

Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy

10.1200/jco.18.01314 · 2019 · External reference

Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL6 rearrangements: a study of 60 cases

10.1016/j.modpat.2025.100710 · 2025 · External reference

Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas

10.1097/pas.0b013e31826cebad · 2013 · External reference

Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium

10.1200/jco.19.00743 · 2019 · External reference

The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms

10.1038/s41375-022-01620-2 · 2022 · External reference

The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee

10.1182/blood.2022015851 · 2022 · External reference

Unresolved reference

2025 · External reference

Outcomes of patients with double-hit lymphoma who achieve first complete remission

10.1200/jco.2017.72.2157 · 2017 · External reference

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

10.1111/bjh.12982 · 2014 · External reference

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis

10.1111/bjh.13463 · 2015 · External reference

Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States

10.3324/haematol.2022.281461 · 2023 · External reference

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

10.1016/s2352-3026(18)30177-7 · 2018 · External reference

Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303

10.1200/jco.18.01994 · 2019 · External reference

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

10.1182/blood-2003-05-1545 · 2004 · External reference

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

10.1038/s41467-023-42585-9 · 2023 · External reference

Revisiting Reddy: a DLBCL do-over

10.1101/2023.11.21.567983 · External reference

Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases

10.1158/1078-0432.ccr-16-1922 · 2017 · External reference

Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study

10.1158/1078-0432.ccr-15-2305 · 2016 · External reference

TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma

10.1038/s41591-020-0757-z · 2020 · External reference

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

10.1182/blood.2019003535 · 2020 · External reference

Genetic and functional drivers of diffuse large B cell lymphoma

10.1016/j.cell.2017.09.027 · 2017 · External reference

Genetics and pathogenesis of diffuse large B-cell lymphoma

10.1056/nejmoa1801445 · 2018 · External reference

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

10.1016/j.ccell.2021.10.006 · 2021 · External reference

Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes

10.1182/blood-2024-198931 · 2024 · External reference

Exploring Tp53 biology in diffuse large B-cell lymphoma: a genomic and transcriptomic meta-analysis [abstract]

10.1097/01.hs9.0000971776.46520.5e · 2023 · External reference

A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study

10.1038/s41408-024-01194-5 · 2024 · External reference

Mutational landscape of high-grade B-cell lymphoma with MYC-BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing

10.3324/haematol.2021.279631 · 2021 · External reference

Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants

10.1038/nature03845 · 2005 · External reference

A method and server for predicting damaging missense mutations

10.1038/nmeth0410-248 · 2010 · External reference

CNS prophylaxis is (mostly) futile in DLBCL

10.1038/s44276-024-00087-1 · 2024 · External reference

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis

10.3324/haematol.2023.284281 · 2024 · External reference

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma

10.18632/oncotarget.6262 · 2016 · External reference

Comparing clinical characteristics and outcomes of MYC and BCL6 double hit lymphoma (DHL- BCL6) with other aggressive B-cell lymphomas: understanding the impact of new who and International Consensus Classification

10.1182/blood-2023-190316 · 2023 · External reference

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

10.1038/s41408-024-01148-x · 2024 · External reference

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

10.3324/haematol.2013.091827 · 2014 · External reference

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma

10.1007/s00277-020-04140-0 · 2020 · External reference

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

10.1182/blood-2018-07-862862 · 2019 · External reference

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B-cell fate and lymphomagenesis

10.1016/j.ccell.2024.03.012 · 2024 · External reference

MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations

10.1111/ejh.12212 · 2014 · External reference

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

10.1182/blood.2024024251 · 2024 · External reference

The rearrangement partner and the presence of MYC mutations determines outcome of patients with MYC and BCL6 rearrangements

2025 · External reference

Single-center analysis of characteristics and outcomes of de novo, concurrent, and transformed diffuse large B-cell lymphoma

10.1002/onco.13846 · 2021 · External reference

Outcomes of the transformation to diffuse large B-cell lymphoma in Hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study

10.1007/s00277-025-06395-x · 2025 · External reference

Cell of origin of transformed follicular lymphoma

10.1182/blood-2015-06-649905 · 2015 · External reference

Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma

10.3324/haematol.2020.255950 · 2021 · External reference

c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover

10.1182/blood.v95.6.2104 · 2000 · External reference

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

10.3324/haematol.2020.274258 · 2022 · External reference